Latest Recruitment News

Entropy Neurodynamics has successfully administered its proprietary IV-infused psilocin, TRP-8803, to the first patient in a clinical trial targeting Binge Eating Disorder, marking a world first in neuropsychiatric treatment.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.

Wide Open Agriculture shakes up its leadership with a new board appointment and plans to recruit a CEO experienced in scaling plant protein businesses, signaling a strategic push to globalise its lupin protein technology.

Dateline Resources reports strong progress on its Colosseum Gold-Rare Earth Project in California, buoyed by soaring gold prices and growing US investor interest. The company is advancing its feasibility study with construction planned post-completion.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

PeopleIN Group reported a challenging FY25 with revenue down 6.5% and EBITDA down 10%, yet strengthened its balance sheet through debt reduction and a strategic sale. The company is poised to capitalise on Queensland's infrastructure boom and Defence sector opportunities.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Lion Rock Minerals has kicked off a large-scale infill drilling program at its Minta Est project in Cameroon, focusing on high-value minerals including rutile, zircon, and rare-earth elements monazite and xenotime. This move builds on recent discoveries and a strategic partnership with Tronox Holdings.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Fleetwood Limited has announced the immediate departure of CEO Bruce Nicholson, with Chair John Klepec stepping in as interim CEO while a search for a permanent replacement begins.

Belararox Ltd announces the immediate resignation of founding Managing Director Arvind Misra, with Chairman Neil Warburton stepping in as interim leader during the search for a new executive director.